Aerosol interferon for RSV pneumonia in toddlers
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 3 years old.
- They must have tested positive for RSV and have symptoms like fever, cough, and wheezing.
- Symptoms must have started within the last 72 hours.
- Your child must not have severe breathing problems or other serious complications.
- They must not have used certain antiviral drugs or immunoglobulin in the past 30 days.
- A parent or legal guardian must sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SIBP-A16 to help protect infants from RSV, a common virus that can cause serious breathing problems. It is for preterm and full-term infants under 1 year old who are entering their first RSV season.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
This study tests a medication called palivizumab to help protect certain children from severe RSV (a common respiratory virus). It is for infants and young children with a higher chance of getting very sick from RSV, such as premature babies or those with certain heart or lung conditions.
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.